356 related articles for article (PubMed ID: 33086429)
1. The feasibility of polypill for cardiovascular disease prevention in Asian Population.
Sukonthasarn A; Chia YC; Wang JG; Nailes J; Buranakitjaroen P; Van Minh H; Verma N; Hoshide S; Shin J; Turana Y; Tay JC; Teo BW; Siddique S; Sison J; Zhang YQ; Wang TD; Chen CH; Kario K
J Clin Hypertens (Greenwich); 2021 Mar; 23(3):545-555. PubMed ID: 33086429
[TBL] [Abstract][Full Text] [Related]
2. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
Roy A; Naik N; Srinath Reddy K
Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
[TBL] [Abstract][Full Text] [Related]
3. The concept of the polypill in the prevention of cardiovascular disease.
Wiley B; Fuster V
Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
[TBL] [Abstract][Full Text] [Related]
4. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
[TBL] [Abstract][Full Text] [Related]
5. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Polypill on Adherence and Cardiovascular Outcomes: A Comprehensive Systematic Review with Meta-Analysis.
Salim H; Musmar B; Saifi M; Ayyad M; Ruzieh M; Azar J; Nazzal Z
Curr Cardiol Rev; 2024; 20(2):61-71. PubMed ID: 38265377
[TBL] [Abstract][Full Text] [Related]
7. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Carey KM; Comee MR; Donovan JL; Kanaan AO
Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries.
Webster R; Patel A; Selak V; Billot L; Bots ML; Brown A; Bullen C; Cass A; Crengle S; Raina Elley C; Grobbee DE; Neal B; Peiris D; Poulter N; Prabhakaran D; Rafter N; Stanton A; Stepien S; Thom S; Usherwood T; Wadham A; Rodgers A;
Int J Cardiol; 2016 Feb; 205():147-156. PubMed ID: 26736090
[TBL] [Abstract][Full Text] [Related]
9. Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.
López-Jaramillo P; González-Gómez S; Zarate-Bernal D; Serrano A; Atuesta L; Clausen C; Castro-Valencia C; Camacho-Lopez P; Otero J
Ther Adv Cardiovasc Dis; 2018 Jun; 12(6):169-174. PubMed ID: 29546816
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Roshandel G; Khoshnia M; Poustchi H; Hemming K; Kamangar F; Gharavi A; Ostovaneh MR; Nateghi A; Majed M; Navabakhsh B; Merat S; Pourshams A; Nalini M; Malekzadeh F; Sadeghi M; Mohammadifard N; Sarrafzadegan N; Naemi-Tabiei M; Fazel A; Brennan P; Etemadi A; Boffetta P; Thomas N; Marshall T; Cheng KK; Malekzadeh R
Lancet; 2019 Aug; 394(10199):672-683. PubMed ID: 31448738
[TBL] [Abstract][Full Text] [Related]
11. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Soliman EZ; Mendis S; Dissanayake WP; Somasundaram NP; Gunaratne PS; Jayasingne IK; Furberg CD
Trials; 2011 Jan; 12():3. PubMed ID: 21205325
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
[TBL] [Abstract][Full Text] [Related]
13. Polypill Variants (Quarter Pill Trials).
Teo K; Yusuf S
Am J Hypertens; 2018 Jun; 31(7):758-761. PubMed ID: 29554202
[TBL] [Abstract][Full Text] [Related]
14. Polypill: Progress and Challenges to Global Use--Update on the Trials and Policy Implementation.
Webster R; Rodgers A
Curr Cardiol Rep; 2015 Dec; 17(12):121. PubMed ID: 26497041
[TBL] [Abstract][Full Text] [Related]
15. Fixed-dose combination therapy to reduce the growing burden of cardiovascular disease in low- and middle-income countries: feasibility and challenges.
Nansseu JR; Tankeu AT; Kamtchum-Tatuene J; Noubiap JJ
J Clin Hypertens (Greenwich); 2018 Jan; 20(1):168-173. PubMed ID: 29316126
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.
Jowett S; Barton P; Roalfe A; Fletcher K; Hobbs FDR; McManus RJ; Mant J
PLoS One; 2017; 12(9):e0182625. PubMed ID: 28873416
[TBL] [Abstract][Full Text] [Related]
17. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC
Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054
[TBL] [Abstract][Full Text] [Related]
18. Polypill Programs to Prevent Stroke and Cut Costs in Low Income Countries: Moving From Clinical Efficacy to Pragmatic Implementation.
Sarfo FS; Nichols M; Opare-Addo PA; Ovbiagele B
Stroke; 2023 Feb; 54(2):407-414. PubMed ID: 36689592
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of a Polypill to Reduce Cardiovascular Events: A Review of Clinical Trials.
Kelly MS; Dacey A; Siana A; Ojeda J
J Cardiovasc Pharmacol; 2024 Jan; 83(1):8-15. PubMed ID: 37924288
[TBL] [Abstract][Full Text] [Related]
20. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
